Arnau Monforte

Arnau Monforte

Auto-generated profile, based on publicly available information

Arnau Monforte

Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Vall d'Hebron Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EMEster Marquez-Algaba
Ester Marquez-Algaba
GIGloria Iacoboni
Gloria Iacoboni
BPBerta Pernas
Berta Pernas
JEJuliana Esperalba
Juliana Esperalba
ILIbai Los-Arcos
Ibai Los-Arcos
IRIsabel Ruíz-Camps
Isabel Ruíz-Camps
Data are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity, and management of CMV infection in patients with aggressive B cell lymphoma treated with CAR T cell therapy. In this retrospective observational study, we analyzed CMV viral load and its clinical impact in patients with aggressive B cell lymphoma receiving CAR T cell therapy between July 2018 and December 2021 at a single center. Patients with a negative baseline CMV IgG or a previous allogeneic stem cell transplantation were excluded. CMV replication was determined in whole blood. Overall, 105 patients met the study's inclusion criteria. Ten patients presented with CMV replication before CAR T cell infusion and were analyzed separately. Forty-two of the remaining 95 patients (44%) had at least 1 positive CMV determination, with a viral load ≥1000 IU/mL in 21 patients (22%). Four patients in the main cohort (N = 95) and 4 patients in the preinfusion replication group (N = 10) achieved a viral load >10,000 IU/mL. Only 7 patients received preemptive antiviral treatment. No CMV end-organ disease was reported. The sole independent risk factor associated with CMV viremia ≥1000 IU/mL was dexamethasone treatment (odds ratio, 8.4; 95% confidence interval, 2.4 to 36.6; P = .002). Based on our findings, we designed an algorithm for CMV management in this setting. CMV replication is relatively frequent in patients with aggressive B cell lymphoma receiving CAR T cell therapy. It is usually self-limited and not associated with end-organ disease. Patients receiving dexamethasone or harboring CMV replication before infusion might benefit from active surveillance and preemptive treatment strategies.

12 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AMAdrian-Sanchez Montalva
Adrian-Sanchez Montalva
JSJúlia Sellarès-Nadal
Júlia Sellarès-Nadal
JEJuan Espinosa-Pereiro
Juan Espinosa-Pereiro
NFNúria Fernández-Hidalgo
Núria Fernández-Hidalgo
SPSantiago Pérez-Hoyos
Santiago Pérez-Hoyos
BABenito Almirante
Benito Almirante
Background: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19) despite the scarcity of evidence. Methods: We report the preliminary results from the Vall d’Hebron prospective cohort study at Vall d’Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and who were treated with tocilizumab until March 25 th . The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. Results: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1-4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5-11) days. The median time from symptom onset to the first dose of tocilizumab was 9 (7-11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3 to 8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8 to 5.8) if tocilizumab was administered after the onset of ARDS. Conclusion: Time from lung injury onset to tocilizumab administration may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data from clinical trials becomes available. Summary of the article’s main point: In patient with COVID-19 and lung injury, time from lung injury onset to tocilizumab administration may be critical to patient recovery. Early administration of host-directed therapies may improve patient outcome.

9 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ASAbiu Sempere
Abiu Sempere
Fernando SalvadorFernando Salvador
Fernando Salvador
AMArnau Monforte
Arnau Monforte
JSJúlia Sampol
Júlia Sampol
JEJuan Espinosa-Pereiro
Juan Espinosa-Pereiro
BABenito Almirante
Benito Almirante
The aim of this study was to describe and compare the clinical characteristics of hospitalized patients with COVID-19 pneumonia according to their geographical origin. This is a retrospective case-control study of hospitalized patients with confirmed COVID-19 pneumonia treated at Vall d’Hebron University Hospital (Barcelona) during the first wave of the pandemic. Cases were defined as patients born in Latin America and controls were randomly selected among Spanish patients matched by age and gender. Demographic and clinical variables were collected, including comorbidities, symptoms, vital signs and analytical parameters, intensive care unit admission and outcome at 28 days after admission. Overall, 1080 hospitalized patients were registered: 774 (71.6%) from Spain, 142 (13.1%) from Latin America and the rest from other countries. Patients from Latin America were considered as cases and 558 Spanish patients were randomly selected as controls. Latin American patients had a higher proportion of anosmia, rhinorrhea and odynophagia, as well as higher mean levels of platelets and lower mean levels of ferritin than Spanish patients. No differences were found in oxygen requirement and mortality at 28 days after admission, but there was a higher proportion of ICU admissions (28.2% vs. 20.2%, p = 0.0310). An increased proportion of ICU admissions were found in patients from Latin America compared with native Spanish patients when adjusted by age and gender, with no significant differences in in-hospital mortality.

10 June 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
AMArnau Monforte
Arnau Monforte
MMM. Teresa Martin-Gomez
M. Teresa Martin-Gomez
CBCristina Berastegui
Cristina Berastegui
EMEster Márquez-Algaba
Ester Márquez-Algaba
JSJudith Sacanell
Judith Sacanell
ILIbai Los-Arcos
Ibai Los-Arcos
Lung transplant recipients (LTR) are highly susceptible to Aspergillus infection (AI), but diagnosis may be limited by the invasiveness of bronchoalveolar lavage fluid (BALF) collection. Proximal airway samples may provide a less invasive alternative. We conducted a retrospective single-center study including all adult LTR (March 2018–March 2022) who underwent bronchoscopy with tracheobronchial aspirate (TBA) and BALF galactomannan (GM) testing in the same procedure. They were processed for mycological culture and EIA-based GM (Bio-Rad) after cysteine homogenization. AI was defined according to ISHLT consensus. A ROC curve for TBA GM and its diagnostic performance were assessed. A total of 545 paired TBA–BALF samples from 282 LTR were analyzed. Proven or probable AI was diagnosed in 22 samples (4%). The optimal TBA GM cut-off was ≥0.54 optical density index (ODI), yielding 95.2% sensitivity, 92% specificity, and an AUC of 0.97 (95% CI, 0.95–0.99). In comparison, BALF GM at ≥1.0 ODI showed 33.3% sensitivity and 99.6% specificity (AUC 0.88, 95% CI, 0.80–0.95) although BALF GM values were significantly higher in invasive infections compared with non-invasive infections (1.49 vs 0.14; P -value = 0.007). TBA cultures were more frequently positive than BALF (24% vs 9.9%). Finally, TBA and BALF GM values demonstrated moderate correlation ( r = 0.54), and combined testing with concordant results improved accuracy to 99.6%. TBA GM demonstrated higher sensitivity than BALF GM for detecting AI in LTR, while maintaining high specificity. Proximal airway samples could complement BALF in future diagnostic strategies. IMPORTANCE: This study provides evidence that galactomannan antigen testing (GM) in tracheobronchial aspirate (TBA) is a highly sensitive, reliable, and less invasive diagnostic tool for detecting Aspergillus infection in lung transplant recipients under universal antifungal prophylaxis, compared to the current standard bronchoalveolar lavage fluid (BALF) GM. These findings highlight the diagnostic value of proximal airway specimens, consistent with the pathophysiology of post-transplant aspergillosis, which often originates in the bronchial tree and may not be adequately captured by BALF early in the disease course. Importantly, the study shows that combining TBA and BALF GM results yields near-perfect diagnostic accuracy, supporting a complementary diagnostic strategy rather than a replacement approach. Although this is a proof-of-concept study, it fills a critical evidence gap in transplant infectious diseases and lays the groundwork for safer, more accurate, and earlier diagnosis of Aspergillus infection, with potential implications for clinical practice, antifungal stewardship, and future guideline development.

25 January 2024 in Transplant Infectious Disease
Verified
Journal Article
Closed access
AMArnau Monforte
Arnau Monforte
MMM. Teresa Martin-Gomez
M. Teresa Martin-Gomez
ILIbai Los-Arcos
Ibai Los-Arcos
EMEster Marquez-Algaba
Ester Marquez-Algaba
CBCristina Berastegui
Cristina Berastegui
OLOscar Len
Oscar Len

30 October 2025 in JHLT Open
Verified
Journal Article
Open access
JSJose Tiago Silva
Jose Tiago Silva
FLFrancisco López-Medrano
Francisco López-Medrano
APAlicia de Pablo
Alicia de Pablo
AGAndrea Gutierrez-Villanueva
Andrea Gutierrez-Villanueva
Ana Fernández-CruzAna Fernández-Cruz
Ana Fernández-Cruz
JAJosé Maria Aguado
José Maria Aguado
Aspergillus is a life-threatening opportunistic pathogen in lung transplant recipients (LuTRs). Isavuconazole (ISA) is a broad-spectrum triazole with favorable pharmacokinetics and safety profile. The clinical experience with ISA in LuTRs, however, is still limited. We performed an ambispective observational study from June 2019 to June 2024 in 5 Spanish centers. Adult LuTRs with isolation of Aspergillus spp. in respiratory tract specimens and indication of ISA therapy (either for the treatment of invasive pulmonary aspergillosis [IPA] or tracheobronchial aspergillosis [TBA] or for preemptive therapy) were eligible. The safety outcome comprised the occurrence of treatment-emergent adverse events (trAEs) and the need for modification of tacrolimus dose. Effectiveness outcomes included clinical, mycological, and radiological response at the end of treatment (EoT). Overall, 50 LuTRs were included. ISA was administered for a median duration of 101 days (interquartile range: 27-161) for the treatment of IPA (18 [36.0%]) or TBA (27 [54.0%]) and as preemptive therapy (5 [10.0%]). The incidence rates of any trAE and trAE requiring premature ISA discontinuation were 24.0% and 10.0%, respectively. Most patients (35 [70.0%]) completed the planned course of therapy. Tacrolimus daily dose was reduced by a median of one-third in half of the patients (26/48 [54.2%]). Clinical, mycological, and radiological responses at EoT among were achieved in 66.7%, 84.2%, and 64.3% of evaluable patients, respectively. Aspergillosis-attributable mortality at the end of follow-up was 12.0%. ISA was well tolerated in LuTRs and proved to be effective for the treatment of invasive Aspergillus syndromes.